Lista de obras -

Acquired amegakaryocytic thrombocytopenia: potential role of thrombopoietin receptor agonists

artículo científico publicado el 1 de noviembre de 2010

Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults

artículo científico publicado en 2007

Analysis of factors predicting survival in patients with hepatocellular carcinoma treated with percutaneous laser ablation

artículo científico publicado en 2006

Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab

artículo científico publicado en 2008

Biologic aspects of thrombopoietin and the development of novel thrombopoietic agents for clinical use.

artículo científico publicado en 2007

Current status of thrombopoietic agents ⬇️

artículo científico publicado el 1 de abril de 2010

Does Helicobacter pylori eradication therapy result in a platelet count improvement in adults with immune thrombocytopenic purpura regardless of H pylori infection? ASH evidence-based review 2008.

artículo científico publicado en 2008

Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review

artículo científico publicado en 2008

Eltrombopag for the treatment of idiopathic thrombocytopenic purpura ⬇️

artículo científico publicado el 1 de diciembre de 2008

Helicobacter pylori and Chronic ITP.

artículo científico publicado en 2008

Helicobacter pylori eradication in the management of patients with idiopathic thrombocytopenic purpura

artículo científico publicado en 2005

ITP: a historical perspective

artículo científico publicado en 2011

Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management

artículo científico publicado en 2008

Immune thrombocytopenic purpura: the treatment paradigm

artículo científico publicado en 2009

Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia

artículo científico publicado en 2007

Infectious causes of chronic immune thrombocytopenia

artículo científico publicado en 2009

Infliximab chimeric antitumor necrosis factor-a monoclonal antibody as potential treatment for myelodysplastic syndromes.

artículo científico publicado en 2005

International consensus report on the investigation and management of primary immune thrombocytopenia

artículo científico publicado en 2010

Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopenia

artículo científico publicado en 2006

Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials

artículo científico publicado en 2013

Management of cancer-related anemia with erythropoietic agents: doubts, certainties, and concerns.

artículo científico publicado en 2005

Management of immune thrombocytopenic purpura in adults

artículo científico publicado en 2004

Mycophenolate mofetil therapy for severe immune thrombocytopenia

artículo científico publicado en 2015

Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura

artículo científico publicado en 2008

Pathobiology and Treatment of Hepatitis Virus-Related Thrombocytopenia ⬇️

artículo científico publicado el 25 de noviembre de 2009

Pathobiology of secondary immune thrombocytopenia

artículo científico publicado en 2009

Pathophysiology and therapeutic options in primary immune thrombocytopenia ⬇️

artículo científico publicado el 26 de noviembre de 2010

Percutaneous laser ablation in patients with isolated unresectable liver metastases from colorectal cancer: Results of a phase II study

artículo científico publicado en 2006

Percutaneous laser ablation in the treatment of hepatocellular carcinoma with small tumors: analysis of factors affecting the achievement of tumor necrosis

artículo científico publicado en 2005

Percutaneous laser ablation of unresectable primary and metastatic adrenocortical carcinoma

artículo científico publicado en 2007

Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review

artículo científico publicado en 2009

Repeated courses of rituximab in chronic ITP: Three different regimens

artículo científico publicado en 2009

Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura

artículo científico publicado en 2007

Rituximab in B-cell disorders other than non-Hodgkin's lymphoma.

artículo científico publicado en 2002

Rituximab in autoimmune hematologic diseases: not just a matter of B cells

artículo científico publicado en 2010

Rituximab treatment of chronic idiopathic thrombocytopenic purpura. Results of a phase II study

artículo científico publicado en 2002

Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura

artículo científico publicado el 1 de diciembre de 2010

Secondary immune thrombocytopenic purpura

artículo científico publicado en 2007

Should medical treatment options be exhausted before splenectomy is performed in adult ITP patients? A debate ⬇️

artículo científico publicado el 15 de septiembre de 2010

Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura?

artículo científico publicado en 2007

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

artículo científico publicado en 2008

Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes

artículo científico publicado en 2002

The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura

artículo científico publicado en 2004

The stingy bone marrow and the wasteful peripheral blood: a tale of two ITPs

artículo científico publicado en 2011

Therapeutic strategies for hepatitis- and other infection-related immune thrombocytopenias

artículo científico publicado en 2009

Thrombopoietic agents

artículo científico publicado en 2010

Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study

artículo científico publicado en 2005

Lista de obras de

Acquired amegakaryocytic thrombocytopenia: potential role of thrombopoietin receptor agonists

Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults

Analysis of factors predicting survival in patients with hepatocellular carcinoma treated with percutaneous laser ablation

Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab

Biologic aspects of thrombopoietin and the development of novel thrombopoietic agents for clinical use.

Current status of thrombopoietic agents ⬇️

Does Helicobacter pylori eradication therapy result in a platelet count improvement in adults with immune thrombocytopenic purpura regardless of H pylori infection? ASH evidence-based review 2008.

Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review

Eltrombopag for the treatment of idiopathic thrombocytopenic purpura ⬇️

Helicobacter pylori and Chronic ITP.

Helicobacter pylori eradication in the management of patients with idiopathic thrombocytopenic purpura

ITP: a historical perspective

Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management

Immune thrombocytopenic purpura: the treatment paradigm

Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia

Infectious causes of chronic immune thrombocytopenia

Infliximab chimeric antitumor necrosis factor-a monoclonal antibody as potential treatment for myelodysplastic syndromes.

International consensus report on the investigation and management of primary immune thrombocytopenia

Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopenia

Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials

Management of cancer-related anemia with erythropoietic agents: doubts, certainties, and concerns.

Management of immune thrombocytopenic purpura in adults

Mycophenolate mofetil therapy for severe immune thrombocytopenia

Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura

Pathobiology and Treatment of Hepatitis Virus-Related Thrombocytopenia ⬇️

Pathobiology of secondary immune thrombocytopenia

Pathophysiology and therapeutic options in primary immune thrombocytopenia ⬇️

Percutaneous laser ablation in patients with isolated unresectable liver metastases from colorectal cancer: Results of a phase II study

Percutaneous laser ablation in the treatment of hepatocellular carcinoma with small tumors: analysis of factors affecting the achievement of tumor necrosis

Percutaneous laser ablation of unresectable primary and metastatic adrenocortical carcinoma

Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review

Repeated courses of rituximab in chronic ITP: Three different regimens

Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura

Rituximab in B-cell disorders other than non-Hodgkin's lymphoma.

Rituximab in autoimmune hematologic diseases: not just a matter of B cells

Rituximab treatment of chronic idiopathic thrombocytopenic purpura. Results of a phase II study

Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura

Secondary immune thrombocytopenic purpura

Should medical treatment options be exhausted before splenectomy is performed in adult ITP patients? A debate ⬇️

Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura?

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes

The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura

The stingy bone marrow and the wasteful peripheral blood: a tale of two ITPs

Therapeutic strategies for hepatitis- and other infection-related immune thrombocytopenias

Thrombopoietic agents

Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study